CDSCO Approves Biocon's Generic Liraglutide
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
Regulatory Clearance Speed: BEFORE - Generic approvals often required redundant and time-consuming local clinical trials, delaying market entry. NOW - The Rule 101 route allows CDSCO to recognize global regulatory approvals, significantly expediting local clearance for critical therapies.
- ▶
Cost and Accessibility of GLP-1s: BEFORE - Advanced GLP-1 therapies were largely imported, branded, and prohibitively expensive for most Indian patients. NOW - Domestic, generic manufacturing by Biocon will drive down costs and democratize access for India's massive diabetic population.
- ▶
Supply Chain Integration: BEFORE - Indian pharmaceutical companies frequently relied on importing the active pharmaceutical ingredient (API) to formulate complex peptide drugs. NOW - Biocon secured approval for both the Liraglutide drug substance and the final drug product, establishing a fully vertically integrated supply chain within India.
Prelims Angle
NCERT Connection
Practice Questions
Q1
With Reference ToWith reference to the CDSCO approval of Biocon's generic Liraglutide, consider the following statements: 1. Liraglutide is a synthetic analog of the Glucagon-like peptide-1 (GLP-1) used primarily for treating Type 1 diabetes. 2. The drug was approved under the CDSCO Rule 101 framework, which expedites clearance by recognizing approvals from stringent global regulatory authorities. Which of the statements given above is/are correct?